| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10042 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2013-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2015-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015506179-A |
| titleOfInvention |
Polynucleotide for treatment of oncogenic virus polypeptide positive tumor |
| abstract |
The present application relates to a polynucleotide encoding an antigenic polypeptide that induces an immune response against an oncogenic viral polypeptide. Also provided are compositions comprising a polynucleotide encoding an antigenic polypeptide, and methods of use. In the provided methods, the virus may be a human papillomavirus. In some embodiments, a method is provided for killing cells expressing a first oncogenic viral polypeptide in a subject. The method includes administering the composition to the subject in an amount sufficient to elicit an immune response against the first oncogenic viral peptide. The composition herein comprises a pharmaceutically acceptable carrier and the polynucleotide provided herein, and the immune response is effective to cause a cytotoxic effect in the cell. In some embodiments, the polynucleotide comprises a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide may be E6 and the second oncogenic viral polypeptide may be E7. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11112401-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019517522-A |
| priorityDate |
2012-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |